Ascendis Pharma (ASND) Earnings Analysis

Ascendis Pharma (ASND) next reports earnings on 2026-08-06, consensus EPS 1.29 USD. Last quarter (2026-05-07) it beat with EPS 0.32 USD vs 0.1876 USD est (+70.6%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 26.95.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ASND next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate1.29 USD
Revenue estimate0.44B

ASND earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-070.32 USD0.1876 USD+70.6%Beat
2026-02-11-0.64 USD-0.06 USD-966.7%Miss
2025-11-12-1.17 USD-0.41 USD-185.4%Miss
2025-05-01-1.66 USD-1.56 USD-6.4%Miss
2024-11-14-1.81359 USD-1.83467 USD+1.1%Beat
2024-09-03-2.05 USD-1.54 USD-33.1%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

ASND valuation and analyst view

Trailing P/E26.95
Trailing EPS8.213 USD
Price / book27.87
Dividend yield0.00%
Market cap15.67B
Analyst consensusBuy (23 buy / 2 hold / 0 sell)
Avg price target311 USD

Related research pages

Frequently asked questions

When is Ascendis Pharma (ASND)'s next earnings date?

Ascendis Pharma is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 1.29 USD and revenue estimate of 0.44B.

Did ASND beat earnings last quarter?

In its 2026-05-07 report, ASND posted EPS of 0.32 USD versus a 0.1876 USD estimate — a beat of 70.6%.

What is ASND's earnings track record?

Over the last 6 reported quarters with consensus data, ASND beat estimates 2 times (33%).

What is ASND's current P/E ratio and EPS?

ASND trades at a trailing P/E of 26.95 on trailing EPS of 8.213059470976617 USD.

What do analysts rate ASND?

Analyst consensus is "Buy" across 25 ratings (0 strong buy, 23 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 311 USD.